Drug intelligence / Profile preview

TAK-951

Development stage: Phase 2
Lead developer: Takeda
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

TAK-951 is a novel peptide agonist developed by Takeda for the prevention and treatment of nausea and vomiting, particularly postoperative nausea and vomiting (PONV). It acts as a peptide modulator, with its mechanism of action involving modulation of pathways that control emesis. TAK-951 is administered via intravenous or subcutaneous injection. Clinical development has reached Phase 2 for PONV in the United States, but some Phase 1 studies in healthy volunteers have been terminated based on benefit-risk assessments. The drug is not yet approved in any country.

Targets

HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on TAK-951.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-951.

Explore the full profile